Dylan Dupuis
Stock Analyst at Roth MKM
(2.65)
# 1,889
Out of 4,829 analysts
9
Total ratings
44.44%
Success rate
33.17%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dylan Dupuis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CMMB Chemomab Therapeutics | Reinstates: Buy | $7 | $1.26 | +455.56% | 2 | Dec 19, 2023 | |
| IVA Inventiva | Reiterates: Buy | $11 | $3.62 | +203.87% | 2 | Sep 21, 2023 | |
| TERN Terns Pharmaceuticals | Reiterates: Buy | $23 | $3.04 | +656.58% | 3 | Aug 8, 2023 | |
| VKTX Viking Therapeutics | Assumes: Buy | $32 | $27.55 | +16.15% | 1 | May 31, 2023 | |
| UBX Unity Biotechnology | Initiates: Buy | $10 | $0.91 | +993.97% | 1 | May 31, 2023 |
Chemomab Therapeutics
Dec 19, 2023
Reinstates: Buy
Price Target: $7
Current: $1.26
Upside: +455.56%
Inventiva
Sep 21, 2023
Reiterates: Buy
Price Target: $11
Current: $3.62
Upside: +203.87%
Terns Pharmaceuticals
Aug 8, 2023
Reiterates: Buy
Price Target: $23
Current: $3.04
Upside: +656.58%
Viking Therapeutics
May 31, 2023
Assumes: Buy
Price Target: $32
Current: $27.55
Upside: +16.15%
Unity Biotechnology
May 31, 2023
Initiates: Buy
Price Target: $10
Current: $0.91
Upside: +993.97%